Advertisement
UK markets closed
  • FTSE 100

    8,433.76
    +52.41 (+0.63%)
     
  • FTSE 250

    20,645.38
    +114.08 (+0.56%)
     
  • AIM

    789.87
    +6.17 (+0.79%)
     
  • GBP/EUR

    1.1622
    +0.0011 (+0.09%)
     
  • GBP/USD

    1.2525
    +0.0001 (+0.01%)
     
  • Bitcoin GBP

    48,558.38
    -1,610.17 (-3.21%)
     
  • CMC Crypto 200

    1,260.82
    -97.19 (-7.16%)
     
  • S&P 500

    5,222.68
    +8.60 (+0.16%)
     
  • DOW

    39,512.84
    +125.08 (+0.32%)
     
  • CRUDE OIL

    78.20
    -1.06 (-1.34%)
     
  • GOLD FUTURES

    2,366.90
    +26.60 (+1.14%)
     
  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     
  • HANG SENG

    18,963.68
    +425.87 (+2.30%)
     
  • DAX

    18,772.85
    +86.25 (+0.46%)
     
  • CAC 40

    8,219.14
    +31.49 (+0.38%)
     

Company News For Jun 19, 2018

MEET vs. WDAY: Which Stock Is the Better Value Option?
  • JD.com, Inc.’s JD shares increased 0.4% on news that Alphabet, Inc. GOOGL was making an investment of $550 million in the Chinese e-commerce giant.

  • Shares of Valeant Pharmaceuticals International, Inc. VRX declined 12.3% after one of its lotions intended to treat plaque psoriasis failed to earn approval from the Food and Drug Administration.

  • Solid Biosciences Inc.’s SLDB shares jumped 10.9% after the company announced that the Food and Drug Administration had lifted the clinical hold on its treatment for Duchenne muscular dystrophy

  • Shares of Tesla, Inc. TSLA rose 3.5% after its CEO Elon Mask unveiled the company’s new production line in a tweet over the weekend


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
JD.com, Inc. (JD) : Free Stock Analysis Report
 
Alphabet Inc. (GOOGL) : Free Stock Analysis Report
 
Tesla, Inc. (TSLA) : Free Stock Analysis Report
 
Valeant Pharmaceuticals International, Inc. (VRX) : Free Stock Analysis Report
 
Solid Biosciences Inc. (SLDB) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research